Form 4: Arteris Director Sells Shares Under 10b5-1 Plan

Arteris, Inc. Director Saiyed Atiq Raza has reported the sale of company stock valued at over $1.5 million through a pre-arranged trading plan.

Summary

• Director Saiyed Atiq Raza reported transactions involving Arteris, Inc. common stock on April 17 and April 20, 2026.
• These transactions were executed under a Rule 10b5-1 trading plan adopted on November 7, 2025.
• A total of 72,940 shares were sold on April 17, 2026, at a weighted average price of $22.1589.
• An additional 17,060 shares were sold on April 20, 2026, at a weighted average price of $22.162.
• The shares sold were part of the holdings of the Saiyed Atiq Raza and Nandini Saraiya 2012 Revocable Trust, for which Mr. Raza serves as trustee.
• Following these transactions, the trust's beneficial ownership of Arteris, Inc. common stock is reported as 300,000 shares.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this filing as neutral to slightly negative due to the significant sale of shares by a director, despite the use of a 10b5-1 plan. While the plan itself is a positive governance practice, the substantial divestment could signal a lack of confidence or a need for personal liquidity.

Positives

• The transactions were conducted under a Rule 10b5-1 plan, which is designed to provide an affirmative defense against allegations of insider trading by establishing a predetermined plan for buying or selling securities.
• The adoption of the plan in November 2025 suggests proactive and planned financial management by the director.
• The weighted average sale prices indicate a consistent market valuation for the shares during the reporting period.

Negatives

• A significant number of shares, totaling 90,000, were sold by a director, which could be perceived negatively by the market.
• The total value of shares sold is approximately $1.5 million, indicating a substantial divestment.

Risks

• Potential for negative market perception due to a director's significant stock sale, even if conducted under a 10b5-1 plan.
• The weighted average sale prices indicate a range of $22.00 to $22.46 for the April 17th sale and $22.05 to $22.24 for the April 20th sale, suggesting potential downward price pressure or a desire to exit at prevailing market rates.

Future Outlook

The filing does not contain forward-looking statements or guidance. It solely reports past transactions.

Industry Context

StockSavvy.ai notes that Form 4 filings are standard disclosures for insider transactions. The use of a 10b5-1 plan by a director of Arteris, Inc. (a company in the semiconductor IP sector) is a common practice to manage personal investments while adhering to insider trading regulations. The volume of shares sold, while significant in absolute terms, needs to be assessed against the director's total holdings and the company's overall market capitalization.

Corporate Governance

Stakeholder Impact

• Shareholders: May perceive the director's sale as a negative signal, potentially impacting share price, although the 10b5-1 plan mitigates insider trading concerns.
• Management: The sale by a director might influence internal discussions on stock valuation and future performance expectations.
• Creditors: No direct impact expected as the transaction involves equity ownership.

Next Steps

• Monitor future Form 4 filings for any further transactions by Mr. Raza or other insiders.
• Observe the market's reaction to this sale and its potential impact on Arteris, Inc.'s stock price.

Key Dates

Recommendation

The filing reports a stock sale by a director under a 10b5-1 plan. While the sale itself is a notable event, the use of a pre-arranged plan suggests it was planned and not based on immediate non-public information. The sale does not provide sufficient information to warrant a strong buy or sell recommendation, making 'hold' the most prudent stance pending further company performance data or strategic announcements.

Keywords

Arteris Inc, Form 4, SEC Filing, Insider Trading, 10b5-1 Plan, Stock Sale, Director Transactions, Beneficial Ownership, Saiyed Atiq Raza, Common Stock